最新ニュース Jiuzi Hldgs (NASDAQ:JZXN) 株価情報

Jiuzi Hldgs

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.

Jiuzi Holdings Inc

Trading Ideas

APVO

Aptevo Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 39%

Wells Fargo analyst Zachary Fadem upgrades Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from Underweight to Equal-Weight and raises the price target from $95 to $130.

News

Upgrades

Price Target

Analyst Ratings

Wells Fargo Upgrades Brinker International to Equal-Weight, Raises Price Target to $130

Oppenheimer analyst Chris Kotowski maintains StepStone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NASDAQ">STEP</a>) with a Outperform and raises the price target from $73 to $84.

STEP

Oppenheimer Maintains Outperform on StepStone Group, Raises Price Target to $84

Journal is the official publication of the International Union of Immunological Societies
Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL&#xAE; siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today its manuscript, Self-delivering RNAi Immunotherapeutic PH-762 Silences PD-1 to Generate Local and Abscopal Anti-tumor Efficacy, has been published in the December, 2024 issue of Frontiers in Immunology.
The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1, is currently in clinical development for advanced cutaneous malignancies. Phio recently presented data from its second cohort in its on-going Phase 1b clinical trial showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).

Biotech

General

PHIO

Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024 Issue Of Frontiers In Immunology

Oppenheimer analyst Chris Kotowski maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $17 to $21.

Oppenheimer Maintains Outperform on P10, Raises Price Target to $21

Oppenheimer analyst Chris Kotowski maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $153 to $175.

Oppenheimer Maintains Outperform on KKR, Raises Price Target to $175

MULN

Mullen Subsidiary, Bollinger Motors, Delivered First 25 B4 Trucks, With Retail Sales Of ~$4.1M Nearly Three Months Since Start Of Production In Sept.

Oppenheimer analyst Chris Kotowski maintains GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) with a Outperform and raises the price target from $18 to $20.

GCMG

Oppenheimer Maintains Outperform on GCM Grosvenor, Raises Price Target to $20

Leerink Partners analyst Daina Graybosch downgrades LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Outperform to Market Perform and lowers the price target from $11 to $2.

Downgrades

LVTX

Leerink Partners Downgrades LAVA Therapeutics to Market Perform, Lowers Price Target to $2

Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, acquired an industrial property located in Red Hook, Brooklyn, New York, on December 11, 2024 for a purchase price of approximately $156.3 million. The purchase price includes the assumption of an approximately $72.9 million 3.85% interest-only loan which matures in March 2028.
The property consists of one 36-foot clear height industrial distribution building containing approximately 312,000 leasable square feet on 16.0 acres. The property is at 280 Richards Street, provides five dock-high and five grade-level loading positions and parking for 349 cars, including 179 rooftop parking positions. The property has riparian access, is 100% leased to a leading e-commerce firm and the estimated stabilized cap rate is 4.8%.

TRNO

Terreno Realty Corporation Acquires Property In Brooklyn, NY, For $156.3M

ExlService Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) has outperformed the market over the past 10 years by 12.17% on an annualized basis producing an average annual return of 23.82%. Currently, ExlService Holdings has a market capitalization of $7.41 billion. 
Buying $1000 In EXLS: If an investor had bought $1000 of EXLS stock 10 years ago, it would be worth $8,802.12 today based on a price of $46.07 for EXLS at the time of writing.
<h3>ExlService Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013823_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXLS

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Zeta Global Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) short percent of float has risen 17.89% since its last report. The company recently reported that it has 15.54 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zeta Global Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zeta Global Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zeta Global Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zeta Global Holdings's peer group average for short interest as a percentage of float is 8.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ZETA

How Is The Market Feeling About Zeta Global Holdings?

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has fallen 69.53% since its last report. The company recently reported that it has 1.59 million shares sold short, which is 0.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

How Is The Market Feeling About Tonix Pharmaceuticals?

3M's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) short percent of float has fallen 4.88% since its last report. The company recently reported that it has 6.34 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>3M Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013810_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for 3M has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing 3M's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, 3M's peer group average for short interest as a percentage of float is 3.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About 3M?

Oppenheimer analyst Chris Kotowski maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Outperform and raises the price target from $24 to $28.

Oppenheimer Maintains Outperform on Blue Owl Cap, Raises Price Target to $28

Castor Maritime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>), ("Castor" or the "Company"), a diversified global shipping company, announces that on December 12, 2024, it entered, through a wholly owned subsidiary, into an Share Purchase Agreement ("SPA") with MPC Münchmeyer Petersen &amp; Co. GmbH ("MPC Holding") for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Münchmeyer Petersen Capital AG (Deutsche Börse, Scale, ISIN DE000A1TNWJ4) ("MPC Capital").
The acquisition price of the shares has been agreed at a price of €7.00 per share, which is equal to an aggregate cost of €182.8 million payable in cash (approx. USD 192.6 million equivalent), excluding any transaction-related costs. As part of the transaction Castor secured a $100,000,000 new senior term loan facility and $50,000,000 proceeds from the issuance of 50,000 additional Series D cumulative convertible preferred shares, both from Toro Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TORO#NASDAQ">TORO</a>), ("Toro"), an entity controlled by Petros Panagiotidis, Castor's Chairman and CEO.

CTRM

TORO

Castor Maritime Enters Into An Share Purchase Agreement With MPC Münchmeyer Petersen & Co. GmbH For The Acquisition Of 26,116,378 Shares Representing 74.09% Of The Shares For ~$192.6M

On Thursday, Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in combination with background therapy in pulmonary <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42456129/keros-therapeutics-announces-update-on-the-phase-2-tropos-trial" rel="noreferrer noopener">arterial hypertension patients</a>.
The move is based on a safety review, as the trial unanticipatedly observed adverse pericardial effusion events.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42297870/keros-therapeutics-licensing-deal-with-takeda-aligns-with-broader-opportunity-for-elritercept-analyst" rel="noreferrer noopener">Keros Therapeutics&#8217; Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst</a>
Pericardial effusion is&nbsp;when too much fluid builds up in the sac around the heart, called the pericardium.&nbsp;This fluid can pressure the heart, making it difficult to function properly.
The TROPOS trial is fully enrolled, and dosing in the 1.5 mg/kg treatment arm remains ongoing following completion of a risk and benefit assessment of the data from the ongoing trial that was conducted by the independent Data Monitoring Committee (DMC) followed by a select group of unblinded individuals at Keros.
The decision to halt the dosing in 3.0 mg/kg and 4.5 mg/kg treatment arms and continue dosing in the 1.5 mg/kg treatment arm was made in consultation with the independent DMC for the trial.
The company intends to continue ongoing safety and efficacy data collection for all treatment arms in the trial.
The company continues to expect to present topline data from all treatment arms in this trial in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40684511/keros-therapeutics-announces-update-on-enrollment-in-the-phase-2-tropos-trial" rel="noreferrer noopener">second quarter of 2025</a>.
Price Action: KROS stock is down 74.1% at $17.80&nbsp;during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42457904/tat-technologies-secures-17-million-mro-deal-with-major-cargo-carrier-to-repair-apus-for-boeing-757-and-767-aircraft" target="_blank" rel="noreferrer noopener">TAT Technologies Secures $17 Million MRO Deal With Major Cargo Carrier: Details</a></li>
</ul>

Health Care

Movers

KROS

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why

JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and maintains $21 price target.

Reiteration

RLAY

JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target

COHN

Cohen & Company Acquires Tax & Wealth Management; Terms Not Disclosed

<ul>
<li>Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery</li>
<li>Factors supporting the go-ahead for the 212-person registration study in the target population include:
<ul>
<li>Multikine led to significant rates of tumor regression</li>
<li>Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit</li>
<li>Target population is likely to show significant survival prolongation in the confirmatory study</li>
</ul>
</li>
<li>Confirmatory study target population selection is based on:
<ul>
<li>Strong statistical significance in a large subgroup of 114 patients</li>
<li>Subgroup analysis was pre-defined in the statistical analysis plan (SAP)</li>
<li>Strong biological rationale for the results based on Multikine's mechanism of action (MOA)</li>
</ul>
</li>
</ul>
CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today highlights strong biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study.

CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer

Jiuzi Holdings enters into non-binding LOI for Shenzhen Maigesong acquisition

LE and DOGZ among Consumer Discretionary movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!



Moving stocks this morning are strong early morning trading, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is rocketing more than 85% with strong early morning trading.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 50% with heavy pre-market trading.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is surging more than 30% with increasing trading activity on Thursday morning.</li>



<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are rising over 21% as it also experiences strong trading today.</li>



<li>A.k.a. Brands (NYSE:<a href="https://investorplace.com/stock-quotes/aka-stock-quote/">AKA</a>) stock is increasing 17% without any clear news this morning.</li>



<li>Orgenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgs-stock-quote/">ORGS</a>) shares are gaining more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318209149&amp;type=PDF&amp;symbol=ORGS&amp;cdn=778bdb482c018a07a4dec09546e61eb2&amp;companyName=Orgenesis+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-04-02">following recent insider buying</a>.</li>



<li>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) stock is climbing over 15% despite a lack of news on Thursday.</li>



<li>AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) shares are jumping more than 15% after releasing its <a href="https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-year-2024-third-quarter-financial-results-updates-fiscal">fiscal Q3 2024 earnings report</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is getting an over 14% boost as it continues to rally on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318212492&amp;type=PDF&amp;symbol=ADXN&amp;cdn=b99f04f9c986cd5ad74a2038763835fe&amp;companyName=Addex+Therapeutics+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-03">neurological company launch</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are up more than 13% without any clear news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Casa Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/casa-stock-quote/">CASA</a>) stock is plummeting over 31% after <a href="https://www.nasdaq.com/press-release/casa-systems-initiates-court-supervised-chapter-11-sale-process-for-businesses-2024">filing for bankruptcy</a>.</li>



<li>View (NASDAQ:<a href="https://investorplace.com/stock-quotes/view-stock-quote/">VIEW</a>) stock is diving more than 29% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318216587&amp;type=PDF&amp;symbol=VIEW&amp;cdn=229f694a9f04258b182e980a2525d125&amp;companyName=View+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-04">alongside a delisting notice</a>.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) shares are tumbling over 27% on Thursday morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is taking a more than 20% beating after <a href="https://finance.yahoo.com/news/flora-growth-corp-announces-launch-003700210.html">launching a share offering</a>.</li>



<li>Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) shares are sliding over 19% alongside its <a href="https://www.nasdaq.com/press-release/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and">Q4 2023 earnings report</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/04/why-is-xti-aerospace-xtia-stock-up-89-today/">after rallying yesterday</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are declining over 13% ahead of its <a href="https://www.nasdaq.com/press-release/reliance-global-group-schedules-fourth-quarter-2023-financial-results-and-business">Q4 conference call</a>.</li>



<li>Jiuzi (NASDAQ:<a href="https://investorplace.com/stock-quotes/jzxn-stock-quote/">JZXN</a>) stock is slipping more than 13% as it continues to fall <a href="https://www.nasdaq.com/press-release/jiuzi-holdings-enters-into-a-non-binding-loi-for-the-acquisition-of-shenzhen">on acquisition plans</a>.</li>



<li>Digital Health Acqsuitiion (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhac-stock-quote/">DHAC</a>) shares are dipping over 13% without any apparent news.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock closes out our pre-market stock movers down more than 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

EC, ABAT and BORR among pre-market losers

Jiuzi Holdings received Nasdaq notification letters

Jiuzi Holdings announces 1-for-13 reverse share split

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has finalized an employment agreement with Huijie Gao, appointing him as Chief F...

Jiuzi Holdings Announces New CFO and Employment Terms

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. reports a substantial increase in total assets, from $11.39 million to $56.22 mi...

Jiuzi Holdings Reports Surge in Total Assets

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has entered into a share purchase agreement to sell all of its 100% equity inter...

Jiuzi Holdings Announces Major Equity Sale

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings Inc. has entered into a Securities Purchase Agreement to sell 500,000 ordinary shares ...

Jiuzi Holdings Sells Shares to International Investors

ABAT

ABIO

ACHL

ADXN

ANGO

AUVI

BORR

BROG

CADL

CASA

DHAC

DOGZ

DXYZ

EGOX

FLGC

GCTS

HSDT

HUBC

JZXN

KYCH

LGVC

LIFW

MAMO

ONMD

ORGS

RELI

REPX

TBIO

ULTA

VIEW

XTIA

ZCMD

Press Releases

Jiuzi Holdings Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

Contracts

Jiuzi Holdings Enters into a Non-Binding LOI for the Acquisition of Shenzhen Maigesong

Jiuzi Holdings Received Nasdaq Notification Letters

Jiuzi Holdings Inc. Announces 1-For-13 Reverse Share Split

Jiuzi Holdings and Shenzhen Maigesong Terminate Negotiations to Focus on Future Growth

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Jiuzi Hldgs

ニュース

最新ニュース Jiuzi Hldgs (NASDAQ:JZXN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル